HKSTP
13.1.2021 12:32:31 CET | Business Wire | Press release
Organised by the Innovation and Technology Commission together with the Hong Kong Science and Technology Parks Corporation, the first City I&T Grand Challenge was launched. In light of the new normal under the epidemic, the theme of the competition this year is “Innovating for Hong Kong’s New Normal” and invites all sectors of the community to put forward innovation and technology (I&T) solutions focusing on two issues, namely environmental sustainability and social connectivity, to tackle problems facing the city and people in their daily lives. A series of workshops and other activities will also be held to create an I&T atmosphere in the whole community.
In his video speech for the launch of the event, the Financial Secretary, Mr Paul Chan, said that the Government has allocated over $100 billion in recent years for I&T infrastructure and development. It has provided full support for nurturing I&T talents and fostering an I&T ecosystem. It is committed to improving the entire I&T industry chain from research and development (R&D) to production and marketing, enabling local I&T talents and enterprises to excel. The COVID-19 epidemic has led people to change their old lifestyles and to think about how to solve problems with technology. He believes that the City I&T Grand Challenge will draw creative ideas from all sectors for developing I&T and smart living proposals to help people live as usual and even in a better way in the new normal during and after the epidemic.
The Secretary for Innovation and Technology, Mr Alfred Sit, said in his video address that, in addition to promoting a diversified economy and injecting new impetus into the economy of Hong Kong, an even more important objective for the Government to push forward I&T development is to improve the quality of life, bringing convenience and benefits to members of the public. Describing the City I&T Grand Challenge as an “I&T marathon”, Mr Sit hoped the whole community could take part in and benefit from it. He also hoped that the City I&T Grand Challenge will fuel community-wide enthusiasm for I&T, especially among young people.
Speaking at the media briefing of the competition, the Commissioner for Innovation and Technology, Ms Rebecca Pun, said that, while some business plan competitions put focus on the team members and product development capabilities of a company and its investment prospects, the City I&T Grand Challenge evaluates each proposal based on its originality, uniqueness and effectiveness, application of innovation and technology, as well as social benefits and impact.
Also speaking at the briefing, the Chief Executive Officer of the Hong Kong Science and Technology Parks Corporation, Mr Albert Wong, said that everyone has the potential to be an innovator to shape the future. The City I&T Grand Challenge offers an invaluable opportunity for the public to apply creativity and develop smart solutions catering to the new normal under the epidemic for the benefit of the community.
The City I&T Grand Challenge is open for application from today till 24 April 2021. Target participants range from primary and secondary school students to local and non-local tertiary students, technology enterprises, R&D teams and entrepreneurs. Winners will be awarded a cash prize and a trophy. For the winners of the University and Open categories, they will also have a chance to receive R&D resources and training for refining their I&T solutions for trying at a designated venue such as a government department or a public organisation.
Under each of the focused issues of environmental sustainability and social connectivity, the City I&T Grand Challenge sets up two specific scenarios for participants to select for developing innovative solutions. For “environmental sustainability”, the two scenarios are surrounding disposable plastic tableware and household food waste, which are pressing environmental problems in the new normal. As regards “social connectivity”, the two scenarios are mainly concerned about the physical and social well-being of senior citizens and children under the new normal of social distancing and distant learning.
The website of the City I&T Grand Challenge has been launched for the public to submit applications. A host of workshops, seminars and training activities will also be organised to introduce knowledge on technologies and entrepreneurship as well as topical daily life issues. All are welcome to join. Details are available at the event website (citytechgc.hk ).
*Videos and images are available for download here .
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
